Arnt Schellekens

Professor of Psychiatry and Addiction at Radboud University Medical Center (Radboudumc)

Data updated

Papers

5 publications

Trials

0 clinical trials

Links

Website

Research Footprint

Arnt Schellekens appears in 5 tracked papers (2016–2024), most studied alongside Ibogaine and Psilocybin, across Substance Use Disorders (SUD), Opioid Use Disorder (OUD) and Depressive Disorders.

Most-cited paper: Therapeutic effect of psilocybin in addiction: A systematic review (112 citations).

Frequent co-authors: Robbert-Jan Verkes.

Background & Research

Arnt Schellekens is a psychiatrist and researcher at Radboud University Medical Center in Nijmegen, the Netherlands. He has focused his career on addiction psychiatry, with research spanning neurobiological mechanisms of addiction, comorbid psychiatric disorders, and innovative treatments for substance use disorders. His publications include clinical and review work on ibogaine and psilocybin in addiction treatment.

Key Impact

He is a Dutch addiction psychiatrist whose work includes ibogaine and psilocybin research in substance use disorders, making him a key clinical researcher at the intersection of addiction psychiatry and psychedelic medicine.

5

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

1 collaborator· click a node to visit their profile

Full network →

Compounds

IbogainePsilocybin

Topics

Substance Use Disorders (SUD)Opioid Use Disorder (OUD)Depressive DisordersAlcohol Use Disorder (AUD)Tobacco/Nicotine Use Disorder (TUD)Bipolar DisorderMedicinal Chemistry & Drug Development

Top Collaborators

Affiliations

Institutions, companies, and organisations Arnt Schellekens is associated with.

Radboud University

Radboud University Medical Center (Radboudumc) is one of the Netherlands' leading academic medical centers, located in Nijmegen. It combines patient care, education, and scientific research under one roof, with a particular strength in neuroscience through its Donders Centre for Medical Neuroscience. Radboudumc is known for its translational research approach. The medical centre bridges fundamental science and clinical practice across areas including oncology, rare diseases, and psychiatry. In the field of psychedelic medicine, Radboudumc has been involved in ibogaine research, conducting studies through its Department of Pharmacology–Toxicology and Department of Psychiatry, examining ibogaine as a potential treatment for opioid use disorder. This work included a clinical study evaluating the cardiac, cerebellar, and psychomimetic safety of ibogaine in opioid-dependent patients, contributing important safety data to the broader scientific understanding of this compound.

View stakeholder →